RTI Biologics Announces 3Q Worldwide Revenues of $42.3M, Up 1%

RTI Biologics, a provider of orthopedic and other biologic implants, has reported worldwide revenues of $42.3 million for the third quarter of 2011, up 1 percent compared to the third quarter of 2010.

Advertisement

Quarterly domestic revenues of $37.3 million for the third quarter of 2011 were comparable to the third quarter of 2010. For the third quarter of 2011, the company reported net income of $2.7 million, compared to a. decrease in net income of $134.7 million due to a goodwill impairment charge in the third quarter 2010.

RTI attributed the third quarter to growth in its surgical specialties and bone graft substitute/general orthopedic implants business.

Related Articles on Devices:

Medtronic Introduces MAST MIDLF Procedure for Minimally Invasive Spinal Fusion

Mazor Robotics Announces 15k Implants Using Robotic Spine Surgery Technology

LDR Receives FDA Clearance for Oblique ALIF Cage

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.